We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

Multimodal Liquid Biopsy Approach Integrates ctDNA, CTC and Protein Biomarkers from Single Blood Sample

By LabMedica International staff writers
Posted on 08 Dec 2023
Print article
Image: NVIGEN X-Precision Medicine Biomarker Profiling technology offers a unique approach to cancer patient monitoring (Photo courtesy of NVIGEN)
Image: NVIGEN X-Precision Medicine Biomarker Profiling technology offers a unique approach to cancer patient monitoring (Photo courtesy of NVIGEN)

Liquid biopsy, a method of analyzing biomarkers present in bodily fluids like blood, presents a less invasive, more accessible, and quicker alternative to traditional tumor biopsies. It has been recognized for a long time that blood or other biological fluids contain measurable markers, such as proteins, nucleic acids, and cells, which are indicative of disease prognosis, recurrence, and overall survival. The discovery of circulating tumor cells (CTCs) in cancer patients dates back to the late 19th century, and over a century later, cell-free DNA (cfDNA) was also identified in cancer patients. In recent years, liquid biopsy has seen a surge in importance, playing a significant role in various aspects of cancer management, including early diagnosis, prognosis, and monitoring drug responses. However, the challenge lies in detecting and quantifying these biomarkers efficiently due to their exceedingly low concentrations in blood samples.

NVIGEN (Santa Clara, CA, USA) has introduced its innovative NVIGEN X-Precision Medicine Biomarker Profiling technology for liquid biopsy. This new approach to cancer patient monitoring uniquely combines the analysis of ctDNA, CTC, and protein biomarkers from a single blood sample. The NVIGEN X comprehensive liquid biopsy utilizes a novel, multimodal approach that integrates ctDNA, CTC, and protein biomarkers. This method is specifically designed to overcome the challenges associated with cancer metastatic recurrence and the limitations of current technologies that primarily focus on ctDNA. These conventional methods often suffer from sub-optimal detection sensitivity and accuracy. NVIGEN's nanoparticle capture platform enables comprehensive and longitudinal cancer monitoring suitable for broad clinical applications through magnetic automation. The technology offers invaluable insights into cancer biology, response to treatments, and potential new therapeutic targets.

In a study that included 36 patient samples, the NVIGEN X technology demonstrated its effectiveness by detecting 2.5 times more variants than traditional methods that rely solely on ctDNA analysis. This study identified key gene alterations like ESR1, ERBB2, and PIK3CA, providing crucial data for making informed treatment decisions. Additionally, the inclusion of protein biomarker analysis in the NVIGEN X technology further enhances its accuracy, thereby supporting personalized diagnostic approaches.

“NVIGEN X exemplifies our commitment to pushing the boundaries of innovation, providing the field with powerful tools for biomarker detection and personalized cancer care,” said Weiwei Gu, Ph.D., NVIGEN VP of Laboratory and Operation. “We are now offering NVIGEN X assays for clinical research uses. It is exciting to see more applications utilizing the unique capabilities of our comprehensive and highly accurate multimodal assays for better biomarker identification, disease dynamics understanding, minimal residual disease monitoring, and treatment management.”

Related Links:

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article



view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more


view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more


view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.